Extracellular Vesicle as a Source of Alzheimer’s Biomarkers: Opportunities and Challenges
Open accessThe DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) is a chronic progressive neurodegenerative disease characterized by memory decline and cognitive dysfunction. Although the primary causes of AD are not clear, it is widely accepted that the accumulation of amyloid beta (Aβ) and consecutive hyper-phosphorylation of tau, synaptic loss, oxidative stress and neuronal death might play a vital role in AD pathogenesis. Recently, it has been widely suggested that extracellular vesicles (EVs), which are released from virtually all cell types, are a mediator in regulating AD pathogenesis. Clinical evidence for the diagnostic performance of EV-associated biomarkers, particularly exosome biomarkers in the blood, is also emerging. In this review, we briefly introduce the biological function of EVs in the central nervous system and discuss the roles of EVs in AD pathogenesis. In particular, the roles of EVs associated with autophagy and lysosomal degradation systems in AD proteinopathy and in disease propagation are discussed. Next, we summarize candidates for biochemical AD biomarkers in EVs, including proteins and miRNAs. The accumulating data brings hope that the application of EVs will be helpful for early diagnostics and the identification of new therapeutic targets for AD. However, at the same time, there are several challenges in developing valid EV biomarkers. We highlight considerations for the development of AD biomarkers from circulating EVs, which includes the standardization of pre-analytical sources of variability, yield and purity of isolated EVs and quantification of EV biomarkers. The development of valid EV AD biomarkers may be facilitated by collaboration between investigators and the industry.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Théry, C., Witwer, K. W., Aikawa, E., Alcaraz, M. J., Anderson, J. D., Andriantsitohaina, R., Antoniou, A., Arab, T., Archer, F., Atkin‐Smith, G. K., et al. (2018) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2018.1535750 · Cited by 11,099 · cited 3×
“More importantly, detailed experimental protocols to isolate EVs from the body fluid, as well as their characteristics, should be presented in a publication [185].”
BackgroundMethodShedding light on the cell biology of extracellular vesicles
van Niel, G., D'Angelo, G., & Raposo, G. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.125 · Cited by 8,369
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155 · cited 1×
“Several modalities have been developed during past decades and effort has been put forward to create diagnostic guidelines for “preclinical” and “clinical” AD (mild cognitive impairment (MCI) and AD) for research purposes by the National Institute on Aging and the Alzheimer’s Association in 2011 [97,98].”
MethodBiogenesis, Secretion, and Intercellular Interactions of Exosomes and Other Extracellular Vesicles
Colombo, M., Raposo, G., & Théry, C. (2014) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-101512-122326 · Cited by 6,186
Hearing loss and cognitive decline in older adults
Lin, F. R., Yaffe, K., Xia, J., Xue, Q.-L., Harris, T. B., Purchase-Helzner, E., Satterfield, S., Ayonayon, H. N., Ferrucci, L., Simonsick, E. M., et al. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.1868 · Cited by 4,017
Kowal, J., Arras, G., Colombo, M., Jouve, M., Morath, J. P., Primdal-Bengtson, B., Dingli, F., Loew, D., Tkach, M., & Théry, C. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521230113 · Cited by 3,426 · cited 1×
“, CD9, CD63, CD81), Alix, HSP70, GTPase and MHC molecules [39,40].”
Rab GTPases as coordinators of vesicle traffic
Stenmark, H. (2009) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2728 · Cited by 3,413
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321
Arroyo, J. D., Chevillet, J. R., Kroh, E. M., Ruf, I. K., Pritchard, C. C., Gibson, D. F., Mitchell, P. S., Bennett, C. F., Pogosova-Agadjanyan, E. L., Stirewalt, D. L., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1019055108 · Cited by 3,294
Routes and mechanisms of extracellular vesicle uptake
Mulcahy, L. A., Pink, R. C., & Carter, D. R. F. (2014) · Journal of Extracellular Vesicles · doi:10.3402/jev.v3.24641 · Cited by 2,832
SNAREs — engines for membrane fusion
Jahn, R., & Scheller, R. H. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2002 · Cited by 2,635
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
The Cellular Phase of Alzheimer’s Disease
De Strooper, B., & Karran, E. (2016) · Cell · doi:10.1016/j.cell.2015.12.056 · Cited by 1,990
High performance plasma amyloid-β biomarkers for Alzheimer's disease
Nakamura, A., Kaneko, N., Villemagne, V. L., Kato, T., Doecke, J., Doré, V., Fowler, C., Li, Q.-X., Martins, R., Rowe, C., et al. (2018) · Nature · doi:10.1038/nature25456 · Cited by 1,681
Depletion of microglia and inhibition of exosome synthesis halt tau propagation
Asai, H., Ikezu, S., Tsunoda, S., Medalla, M., Luebke, J., Haydar, T., Wolozin, B., Butovsky, O., Kügler, S., & Ikezu, T. (2015) · Nature Neuroscience · doi:10.1038/nn.4132 · Cited by 1,591 · cited 4×
“have reported that microglia-derived exosomes lead to the progression of tauopathy [66].”
BackgroundInfluentialHa, D., Yang, N., & Nadithe, V. (2016) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2016.02.001 · Cited by 1,346
Alzheimer’s disease β-amyloid peptides are released in association with exosomes
Rajendran, L., Honsho, M., Zahn, T. R., Keller, P., Geiger, K. D., Verkade, P., & Simons, K. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603838103 · Cited by 1,343 · cited 2×
“Alix and flotillin-1, the marker proteins in exosome-like vesicles, are enriched in the amyloid plaques of AD patient brains [109].”
BackgroundCSF markers for incipient Alzheimer's disease
Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291
Lee, J.-H., Yu, W. H., Kumar, A., Lee, S., Mohan, P. S., Peterhoff, C. M., Wolfe, D. M., Martinez-Vicente, M., Massey, A. C., Sovak, G., et al. (2010) · Cell · doi:10.1016/j.cell.2010.05.008 · Cited by 1,212 · cited 1×
“During autophagy, PSEN1 regulates lysosomal acidification and proteolysis, which is consistent with the report of neurons in AD patients bearing PSEN1 mutation demonstrating lysosomal pathology [81,82].”
ResultSelf-citationThe Intersection of Amyloid Beta and Tau at Synapses in Alzheimer’s Disease
Spires-Jones, T. L., & Hyman, B. T. (2014) · Neuron · doi:10.1016/j.neuron.2014.05.004 · Cited by 1,201
Hébert, S. S., Horré, K., Nicolaï, L., Papadopoulou, A. S., Mandemakers, W., Silahtaroglu, A. N., Kauppinen, S., Delacourte, A., & De Strooper, B. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710263105 · Cited by 1,183 · cited 1×
“In the brain of AD patients, the miR-29a/b-1 cluster is significantly decreased and protein levels of BACE1 are increased [115].”
BackgroundCSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment
Mattsson, N. (2009) · JAMA · doi:10.1001/jama.2009.1064 · Cited by 1,176
Saman, S., Kim, W., Raya, M., Visnick, Y., Miro, S., Saman, S., Jackson, B., McKee, A. C., Alvarez, V. E., Lee, N. C. Y., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.277061 · Cited by 985 · cited 2×
“Exosomes contain a variety of proteins which are implicated in neural function and disorders, such as alpha-synuclein [62], tau [33], amyloid precursor protein (APP), APP C-terminal fragments and amyloid intracellular domain [63].”
BackgroundExogenous Induction of Cerebral ß-Amyloidogenesis Is Governed by Agent and Host
Meyer-Luehmann, M., Coomaraswamy, J., Bolmont, T., Kaeser, S., Schaefer, C., Kilger, E., Neuenschwander, A., Abramowski, D., Frey, P., Jaton, A. L., et al. (2006) · Science · doi:10.1126/science.1131864 · Cited by 971 · cited 1×
“In an animal model, exogenous inoculation of Aβ-containing brain extracts spreads Aβ at the injected site, as well as in the adjacent regions [106,107].”
BackgroundTau phosphorylation: the therapeutic challenge for neurodegenerative disease
Hanger, D. P., Anderton, B. H., & Noble, W. (2009) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2009.01.003 · Cited by 965 · cited 1×
“, protein phosphatase 2A), generates neurofibrillary tangles inside neurons [69].”
BackgroundFiandaca, M. S., Kapogiannis, D., Mapstone, M., Boxer, A., Eitan, E., Schwartz, J. B., Abner, E. L., Petersen, R. C., Federoff, H. J., Miller, B. L., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.06.008 · Cited by 959
ARF6-Regulated Shedding of Tumor Cell-Derived Plasma Membrane Microvesicles
Muralidharan-Chari, V., Clancy, J., Plou, C., Romao, M., Chavrier, P., Raposo, G., & D'Souza-Schorey, C. (2009) · Current Biology · doi:10.1016/j.cub.2009.09.059 · Cited by 912 · cited 1×
“Conversely, these organizations are required for several energy-dependent mechanisms, including the asymmetric movement of the plasma membrane by aminophospholipid translocase [11], membrane curvature [12,13] and cytoskeleton rearrangement [14].”
BackgroundNeurotransmitter-Triggered Transfer of Exosomes Mediates Oligodendrocyte–Neuron Communication
Frühbeis, C., Fröhlich, D., Kuo, W. P., Amphornrat, J., Thilemann, S., Saab, A. S., Kirchhoff, F., Möbius, W., Goebbels, S., Nave, K.-A., et al. (2013) · PLoS Biology · doi:10.1371/journal.pbio.1001604 · Cited by 902
Exosomes are released by cultured cortical neurones
Fauré, J., Lachenal, G., Court, M., Hirrlinger, J., Chatellard-Causse, C., Blot, B., Grange, J., Schoehn, G., Goldberg, Y., Boyer, V., et al. (2006) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2005.12.003 · Cited by 896 · cited 1×
“Extracellular vesicles (EVs) are released from virtually all cell types, including cells in the central nervous system (CNS) such as oligodendrocytes, neurons, astrocytes, microglia and Schwann cells, as well as endothelial cells [1,2].”
BackgroundExtracellular vesicles round off communication in the nervous system
Budnik, V., Ruiz-Cañada, C., & Wendler, F. (2016) · Nature Reviews Neuroscience · doi:10.1038/nrn.2015.29 · Cited by 712 · cited 1×
“Microvesicles and exosomes originate from healthy resting or stimulated cells, while the apoptotic bodies are shed from dying cells [8].”
BackgroundPlasma β-amyloid in Alzheimer's disease and vascular disease
Janelidze, S., Stomrud, E., Palmqvist, S., Zetterberg, H., van Westen, D., Jeromin, A., Song, L., Hanlon, D., Tan Hehir, C. A., Baker, D., et al. (2016) · Scientific Reports · doi:10.1038/srep26801 · Cited by 626
Alzheimer’s disease pathology propagation by exosomes containing toxic amyloid-beta oligomers
Sardar Sinha, M., Ansell-Schultz, A., Civitelli, L., Hildesjö, C., Larsson, M., Lannfelt, L., Ingelsson, M., & Hallbeck, M. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1868-1 · Cited by 527
Plasma tau in Alzheimer disease
Mattsson, N., Zetterberg, H., Janelidze, S., Insel, P. S., Andreasson, U., Stomrud, E., Palmqvist, S., Baker, D., Tan Hehir, C. A., Jeromin, A., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000003246 · Cited by 502 · cited 1×
“For example, immunomagnetic reduction assays [138] or single molecule arrays (SIMOA) have been applied to detect Aβ or tau in plasma [139,140].”
MethodDinkins, M. B., Dasgupta, S., Wang, G., Zhu, G., & Bieberich, E. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.02.012 · Cited by 494
Alteration of the microRNA network during the progression of Alzheimer's disease
Lau, P., Bossers, K., Janky, R., Salta, E., Frigerio, C. S., Barbash, S., Rothman, R., Sierksma, A. S. R., Thathiah, A., Greenberg, D., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201201974 · Cited by 474
Amyloid biomarkers in Alzheimer's disease
Blennow, K., Mattsson, N., Schöll, M., Hansson, O., & Zetterberg, H. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.03.002 · Cited by 470
Aβ Secretion and Plaque Formation Depend on Autophagy
Nilsson, P., Loganathan, K., Sekiguchi, M., Matsuba, Y., Hui, K., Tsubuki, S., Tanaka, M., Iwata, N., Saito, T., & Saido, T. C. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.08.042 · Cited by 459 · cited 1×
“Besides the degradation of Aβ peptides by Aβ-degrading enzymes including neprilysin and insulin-degrading enzyme [72], Aβ can accumulate in the autophagosomes of dystrophic neurites—the main constituents of the neuritic plaque of sporadic AD—and is released from neurons in an autophagy-dependent pathway [73].”
BackgroundZhang, X., Zhou, K., Wang, R., Cui, J., Lipton, S. A., Liao, F.-F., Xu, H., & Zhang, Y.-W. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m608856200 · Cited by 436 · cited 1×
“HIF-1α increases the transcription of β-secretase (BACE1) through the hypoxia-response element and activates the γ-secretase complex through a direct interaction [95,96].”
BackgroundMicroRNA regulation of Alzheimer's Amyloid precursor protein expression
Hébert, S. S., Horré, K., Nicolaï, L., Bergmans, B., Papadopoulou, A. S., Delacourte, A., & De Strooper, B. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.11.009 · Cited by 436
Neuronal Exosomal miRNA-dependent Translational Regulation of Astroglial Glutamate Transporter GLT1
Morel, L., Regan, M., Higashimori, H., Ng, S. K., Esau, C., Vidensky, S., Rothstein, J., & Yang, Y. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.410944 · Cited by 430 · cited 1×
“For instance, miRNAs in exosomes isolated from a conditioned medium of neuronal culture (especially, miR-124a) regulate excitatory amino acid transporter 2, an essential mediator of glutamate uptake through the internalization of exosomes into astrocytes [56].”
BackgroundCheng, L., Doecke, J. D., Sharples, R. A., Villemagne, V. L., Fowler, C. J., Rembach, A., Martins, R. N., Rowe, C. C., Macaulay, S. L., Masters, C. L., et al. (2015) · Molecular Psychiatry · doi:10.1038/mp.2014.127 · Cited by 409 · cited 1×
“Exosome (serum) NC (36) MCI (8) AD (16) qRT-PCR following discovery by sequencing from 23 HC, 3 MCI and 23 AD 16 miRNAs 3 87 77 [173]”
BackgroundTDP-43 stage, mixed pathologies, and clinical Alzheimer’s-type dementia
James, B. D., Wilson, R. S., Boyle, P. A., Trojanowski, J. Q., Bennett, D. A., & Schneider, J. A. (2016) · Brain · doi:10.1093/brain/aww224 · Cited by 407
Decreased synaptic proteins in neuronal exosomes of frontotemporal dementia and Alzheimer's disease
Goetzl, E. J., Kapogiannis, D., Schwartz, J. B., Lobach, I. V., Goetzl, L., Abner, E. L., Jicha, G. A., Karydas, A. M., Boxer, A., & Miller, B. L. (2016) · The FASEB Journal · doi:10.1096/fj.201600816r · Cited by 398
Lucin, K. M., O’Brien, C. E., Bieri, G., Czirr, E., Mosher, K. I., Abbey, R. J., Mastroeni, D. F., Rogers, J., Spencer, B., Masliah, E., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.06.046 · Cited by 374
Proteolytic Degradation of Amyloid -Protein
Saido, T., & Leissring, M. A. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006379 · Cited by 368
Chivet, M., Javalet, C., Laulagnier, K., Blot, B., Hemming, F. J., & Sadoul, R. (2014) · Journal of Extracellular Vesicles · doi:10.3402/jev.v3.24722 · Cited by 340
Absalon, S., Kochanek, D. M., Raghavan, V., & Krichevsky, A. M. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.1327-13.2013 · Cited by 302 · cited 2×
“And miR-26b, which is also increased in AD patients, induces nuclear export and activation of Cdk5, a neuronal kinase involved in the phosphorylation of tau [123].”
BackgroundIraci, N., Leonardi, T., Gessler, F., Vega, B., & Pluchino, S. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17020171 · Cited by 301
Emerging Roles of Extracellular Vesicles in the Nervous System
Rajendran, L., Bali, J., Barr, M. M., Court, F. A., Krämer-Albers, E.-M., Picou, F., Raposo, G., van der Vos, K. E., van Niel, G., Wang, J., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.3258-14.2014 · Cited by 292
The genetic architecture of Alzheimer's disease: beyond APP, PSENs and APOE
Guerreiro, R. J., Gustafson, D. R., & Hardy, J. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.03.025 · Cited by 285 · cited 1×
“PSEN1 has been identified as a major genetic risk factor for early onset familial AD [78].”
BackgroundInduction of cerebral β-amyloidosis: Intracerebral versus systemic Aβ inoculation
Eisele, Y. S., Bolmont, T., Heikenwalder, M., Langer, F., Jacobson, L. H., Yan, Z.-X., Roth, K., Aguzzi, A., Staufenbiel, M., Walker, L. C., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903200106 · Cited by 279
Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer’s disease
Portelius, E., Zetterberg, H., Skillbäck, T., Törnqvist, U., Andreasson, U., Trojanowski, J. Q., Weiner, M. W., Shaw, L. M., & Mattsson, N. (2015) · Brain · doi:10.1093/brain/awv267 · Cited by 279
Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease
Kester, M. I., Teunissen, C. E., Crimmins, D. L., Herries, E. M., Ladenson, J. H., Scheltens, P., van der Flier, W. M., Morris, J. C., Holtzman, D. M., & Fagan, A. M. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.1867 · Cited by 246
MicroRNA Profiling of CSF Reveals Potential Biomarkers to Detect Alzheimer`s Disease
Denk, J., Boelmans, K., Siegismund, C., Lassner, D., Arlt, S., & Jahn, H. (2015) · PLOS ONE · doi:10.1371/journal.pone.0126423 · Cited by 236
Morris, G. P., Clark, I. A., Zinn, R., & Vissel, B. (2013) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2013.07.002 · Cited by 236 · cited 1×
“The neural synaptic plasticity is regulated not only by neuron-specific processes but also by the contribution of glial cells, such as microglia and astrocytes [53].”
BackgroundIncreased CSF neurogranin concentration is specific to Alzheimer disease
Wellington, H., Paterson, R. W., Portelius, E., Törnqvist, U., Magdalinou, N., Fox, N. C., Blennow, K., Schott, J. M., & Zetterberg, H. (2016) · Neurology · doi:10.1212/wnl.0000000000002423 · Cited by 232 · cited 1×
“More importantly, a higher level of CSF neurogranin was not observed in non-AD neurodegenerative diseases [132,133], indicating that neurogranin may be specific to AD.”
BackgroundMiR-107 is Reduced in Alzheimer's Disease Brain Neocortex: Validation Study
Nelson, P. T., & Wang, W.-X. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-091603 · Cited by 222 · cited 1×
“Additionally, miR-107 and -195 show negative correlations with the BACE1 expression levels [116,117].”
BackgroundMicroRNA-195 downregulates Alzheimer's disease amyloid-β production by targeting BACE1
Zhu, H.-C., Wang, L.-M., Wang, M., Song, B., Tan, S., Teng, J.-F., & Duan, D.-X. (2012) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2012.05.018 · Cited by 204
miR-106b impairs cholesterol efflux and increases Aβ levels by repressing ABCA1 expression
Kim, J., Yoon, H., Ramírez, C. M., Lee, S.-M., Hoe, H.-S., Fernández-Hernando, C., & Kim, J. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2011.11.010 · Cited by 202
Self-citationEndocytosis and Autophagy: Exploitation or Cooperation?
Tooze, S. A., Abada, A., & Elazar, Z. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a018358 · Cited by 202
CSF biomarkers cutoffs: The importance of coincident neuropathological diseases
Toledo, J. B., Brettschneider, J., Grossman, M., Arnold, S. E., Hu, W. T., Xie, S. X., Lee, V. M.-Y., Shaw, L. M., & Trojanowski, J. Q. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-0983-7 · Cited by 182
Kester, M. I., Goos, J. D. C., Teunissen, C. E., Benedictus, M. R., Bouwman, F. H., Wattjes, M. P., Barkhof, F., Scheltens, P., & van der Flier, W. M. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.754 · Cited by 161
Reduced expression of hsa-miR-27a-3p in CSF of patients with Alzheimer disease
Sala Frigerio, C., Lau, P., Salta, E., Tournoy, J., Bossers, K., Vandenberghe, R., Wallin, A., Bjerke, M., Zetterberg, H., Blennow, K., et al. (2013) · Neurology · doi:10.1212/01.wnl.0000437306.37850.22 · Cited by 156
CSF sAPPβ, YKL-40, and neurofilament light in frontotemporal lobar degeneration
Alcolea, D., Vilaplana, E., Suárez-Calvet, M., Illán-Gala, I., Blesa, R., Clarimón, J., Lladó, A., Sánchez-Valle, R., Molinuevo, J. L., García-Ribas, G., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004088 · Cited by 123
Downregulated serum miR‐223 servers as biomarker in Alzheimer's disease
Jia, L., & Liu, Y. (2016) · Cell Biochemistry and Function · doi:10.1002/cbf.3184 · Cited by 95
Müller, M., Kuiperij, H. B., Versleijen, A. A. M., Chiasserini, D., Farotti, L., Baschieri, F., Parnetti, L., Struyfs, H., De Roeck, N., Luyckx, J., et al. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160038 · Cited by 41 · cited 1×
“In a multicenter validation study [152], it was reported that the measurement of miRNA in CSF can be biased by several pre-analytical and analytical sources of variability, which may produce inconsistent results.”
Result
Cited by
A brief history of nearly EV‐erything – The rise and rise of extracellular vesicles
Couch, Y., Buzàs, E. I., Di Vizio, D., Gho, Y. S., Harrison, P., Hill, A. F., Lötvall, J., Raposo, G., Stahl, P. D., Théry, C., et al. (2021) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12144 · Cited by 566
Host- and Microbiota-Derived Extracellular Vesicles, Immune Function, and Disease Development
Macia, L., Nanan, R., Hosseini-Beheshti, E., & Grau, G. E. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms21010107 · Cited by 237
“Neurological diseases have been widely studied with an attempt to define the biomarker potential of EVs, notably in multiple sclerosis [47,48] and neurodegenerative diseases [49] as well as in stroke and traumatic brain injury [50].”
BackgroundExtracellular Vesicles in Blood: Sources, Effects, and Applications
Alberro, A., Iparraguirre, L., Fernandes, A., & Otaegui, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158163 · Cited by 170
MicroRNAs in Alzheimer’s Disease: Function and Potential Applications as Diagnostic Biomarkers
Wei, W., Wang, Z.-Y., Ma, L.-N., Zhang, T.-T., Cao, Y., & Li, H. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00160 · Cited by 103
TGF-β Signaling: A Therapeutic Target to Reinstate Regenerative Plasticity in Vascular Dementia?
Kandasamy, M., Anusuyadevi, M., Aigner, K. M., Unger, M. S., Kniewallner, K. M., Sousa, D. M. B. D., Altendorfer, B., Mrowetz, H., Bogdahn, U., & Aigner, L. (2020) · Aging and disease · doi:10.14336/ad.2020.0222 · Cited by 77
Metadata
- Authors
- Lee, S., Mankhong, S., & Kang, J.-H.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2019-04-08
- Volume
- 20
- Issue
- 7
- Pages
- 1728
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2925616201
- Cited by
- 124
- References
- 66
- FWCI
- 5.51
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.